Ratings by CapitalOne (Naureen Quibria)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/29/2024 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
7.54 (1.39) |
-81.56% | Details | |
| 5/17/2024 | Immutep Limited | IMMP | New Coverage | Overweight (N/A) |
2.92 (2.76) |
-5.48% | Details | |
| 8/16/2023 | Immunocore | IMCR | New Coverage | Overweight (N/A) |
25.62 (32.94) |
28.57% | Details | |
| 9/7/2022 | Fennec Pharmaceuticals Inc. | FENC | New Coverage | Overweight (N/A) |
7.35 (7.70) |
4.76% | Details | |
| 9/7/2022 | Chimerix | CMRX | New Coverage | Overweight (N/A) |
2.08 (8.54) |
310.58% | Details |
